# Janus Henderson Investors

Type: Company (JHG)

Source: GetYourBrief — https://getyourbrief.com/entity/janus-henderson-investors
Canonical HTML page: https://getyourbrief.com/entity/janus-henderson-investors

## Timeline

- **2029**: Cash runway into first half of 2029 — Proceeds from the $150 million private placement are expected to fund a planned NDA submission and operations into the first half of 2029.
- **2028**: CRPS-RISE Phase 3 topline results expected — Ambros expects to report topline results from the pivotal CRPS-RISE trial evaluating neridronate in warm CRPS-1.
- **2026-08-21**: Merger and $150M financing announced — Werewolf Therapeutics and Ambros Therapeutics announce a definitive all-stock merger and an oversubscribed $150 million private placement.

## Recent coverage (4 stories, network-wide)

### Neridronate Phase 3 Backed by $150M Merger and Financing
2026-08-22 01:36:06 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Neridronate, an investigational CRPS-1 bisphosphonate already approved in Italy, moves into a 270-patient pivotal CRPS-RISE Phase 3 with FDA Breakthrough, Fast Track, and Orphan designations. The all-stock Werewolf-Ambros merger and oversubscribed $150 million private placement fund development through topline in 2028.
Full story: https://getbiobrief.com/story/neridronate-phase3-150m-merger-financing

### CRPS-1 Patients Gain Hope as $150M Merger Advances Neridronate
2026-08-22 01:34:27 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The Werewolf-Ambros merger creates a Nasdaq-listed company focused on neridronate for CRPS-1, an under-served pain indication affecting 65,000 newly diagnosed U.S. patients yearly. A $150 million financing funds a 270-patient pivotal Phase 3 trial with topline data expected in 2028.
Full story: https://gethealthbrief.com/story/crps1-patients-150m-merger-neridronate

### UnitedHealth Rebound: $378B Healthcare Giant Shakes Off 2025 Headwinds
2026-08-03 18:43:43 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

After a turbulent 2025 marked by cyberattack fallout and operational pressures, UnitedHealth Group is regaining its footing. A key management change has reignited confidence, and the company’s stock is now a top contributor to a major growth fund, signaling a broader sector recovery.
Full story: https://gethealthbrief.com/story/unitedhealth-rebound-healthcare-giant-management-change-2026

### UNH Stock Up 0.35% as $378B Health Giant Returns to Growth Funds
2026-08-03 18:43:36 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2

UnitedHealth Group has emerged as a top contributor in Janus Henderson’s Forty Fund, which returned 19% in Q2 2026. The stock closed at $414.40 on July 31, and its recovery—catalyzed by a management change—has put it back on institutional investors’ radar.
Full story: https://getfinancebrief.com/story/unh-stock-janus-henderson-forty-fund-q2-2026-top-contributor

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.